COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB, VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AFTER ONE-YEAR MAINTENANCE THERAPY FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: 3 MATCHING-ADJUSTED INDIRECT COMPARISONS

Walter Reinisch  ¹     Gil Y. Melmed  ²     Hiroshi Nakase  ³     Jacob Seidelin  ⁴     Christopher Ma  ^{5, 6}     Si Xuan  ⁷     Jacinda Tran  ^{7, 8}     Dapo Ilo  ⁷     Lani Wegrzyn  ⁷     Gwen Levy  ⁷     Yuri Sanchez Gonzalez  ⁷     Remo Panaccione  ^6    
1 Medical University of Vienna, Wien, Austria
² Cedars-Sinai Medical Center, Los Angeles, United States
³ Sapporo Medical University School of Medicine, Sapporo, Japan
⁴ Copenhagen University Hospital - Gentofte and Herlev, Herlev, Denmark
⁵ University of Caglary, Calgary, Canada
⁶ University of Calgary, Calgary, Canada
⁷ AbbVie, Inc., North Chicago, United States
⁸ University of Washington, Seattle, United States

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)